Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Has Average Price Target of $36.46 According to Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have earned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $36.46.

A number of equities research analysts have recently weighed in on JANX shares. Stifel Nicolaus set a $35.00 price objective on Janux Therapeutics in a research note on Friday, August 7th. Wolfe Research raised Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price on the stock in a research note on Monday, August 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a report on Friday, October 16th. Guggenheim lowered their target price on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a report on Friday, August 7th. Finally, TD Cowen raised Janux Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $16.06 on Tuesday. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $35.34. The company’s 50 day simple moving average is $17.52 and its 200-day simple moving average is $15.39. The company has a market capitalization of $981.91 million, a price-to-earnings ratio of -9.79 and a beta of 2.44.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.13. The firm had revenue of $9.29 million during the quarter, compared to analysts’ expectations of $8.03 million. Equities analysts expect that Janux Therapeutics will post -1.70 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Fulcrum Asset Management LLP grew its stake in Janux Therapeutics by 3,391.2% during the 3rd quarter. Fulcrum Asset Management LLP now owns 2,374 shares of the company’s stock worth $40,000 after purchasing an additional 2,306 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Janux Therapeutics by 25.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 209,002 shares of the company’s stock worth $3,545,000 after purchasing an additional 42,910 shares during the period. CenterBook Partners LP raised its position in Janux Therapeutics by 39.1% in the 3rd quarter. CenterBook Partners LP now owns 39,656 shares of the company’s stock valued at $685,000 after purchasing an additional 11,154 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Janux Therapeutics in the 3rd quarter valued at about $54,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al raised its position in Janux Therapeutics by 8.8% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 12,350 shares of the company’s stock valued at $213,000 after purchasing an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.